Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics shares nearly doubled on Monday: explore why
11:16am, Monday, 11'th Oct 2021
Shares of Protagonist Therapeutics Inc (NASDAQ: PTGX) nearly doubled on Monday as the U.S. FDA said it could resume the clinical trials for Rusfertide – an investigational, injectable hepcidin mimet
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
10:33am, Monday, 11'th Oct 2021
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. The post PTGX Stock: The FDA News That Has Protagonist Ther
PTGX Stock: Why It Substantially Increased Today
08:18am, Monday, 11'th Oct 2021
The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) increased by over 80% pre-market today. This is why it happened.
Protagonist Therapeutics shares soar after FDA lifts clinical hold on its experimental cancer drug
08:11am, Monday, 11'th Oct 2021
Shares of Protagonist Therapeutics Inc. PTGX, +0.72% soared 87.0% in premarket trading on Monday after the company said the Food and Drug Administration had lifted a clinical hold on clinical trials o
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
07:00am, Monday, 11'th Oct 2021
NEWARK, Calif., Oct. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has remov
Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy
10:44am, Tuesday, 05'th Oct 2021
When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. The post Battered Protagonist Therapeutics Stock Is Primed F
NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2
Protagonist Therapeutics: How To Buy The Dip
06:14pm, Thursday, 30'th Sep 2021
Today, we revisit Protagonist Therapeutics for the first time in over a year and a half. The stock has cratered in recent trading sessions after the FDA put a clinical hold on a key study.
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. (“Protagonist”
Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last?
09:12am, Wednesday, 22'nd Sep 2021
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGX
02:58pm, Tuesday, 21'st Sep 2021
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTG
Why Protagonist Therapeutics Stock Plunged Today
04:14pm, Monday, 20'th Sep 2021
The FDA has placed a clinical hold on testing of rusfertide.
Why Protagonist Therapeutics Stock Is Tanking Today
02:48pm, Friday, 17'th Sep 2021
The FDA put a clinical hold on one of the biotech's new drug candidates.
PTGX Stock: Why It Significantly Decreased Today
02:10pm, Friday, 17'th Sep 2021
The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) fell over 60% during intraday trading today. This is why it happened.
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program
07:00am, Friday, 17'th Sep 2021
NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S. Food a
